DUXAP8 a Pan-Cancer Prognostic Marker Involved in the Molecular Regulatory Mechanism in Hepatocellular Carcinoma: A Comprehensive Study Based on Data Mining, Bioinformatics, and in vitro Validation
机构:[1]Capital Med Univ, Beijing Tongren Hosp, Dept Gen Surg, 1 Dongjiaominxiang, Beijing 100730, Peoples R China临床科室普外科首都医科大学附属北京同仁医院首都医科大学附属同仁医院[2]Shanxi Med Univ, Clin Med Coll 1, Dept Gen Surg, Hosp 1, 85 Jiefangnan Rd, Taiyuan 030001, Shanxi, Peoples R China[3]St Vincent Hosp, Dept Med, Worcester, MA 01604 USA
Background: Double homeobox A pseudogene 8 (DUXAP8) has been identified as a key regulator at the posttranscriptional level in various types of cancers. However, whether DUXAP8 has a role in hepatocellular carcinoma (HCC) progression remains to be determined. Here, we aimed to investigate the potential clinical value of DUXAP8 as a pan-cancer marker, and its role in HCC development through an integrated analysis strategy and in vitro experimental validation. Methods: Comprehensive analysis was performed using data mined from public databases to evaluate the expression patterns and clinical value of DUXAP8 in human pan-cancers. Bioinformatics analysis was performed to investigate the potential biological functions of DUXAP8 in HCC based on TCGA database. Real-time qPCR analysis was used to examine the expression levels of DUXAP8 in HCC tissue samples and cell lines. DUXAP8-siRNA was used to silence DUXAP8 in the Hep-G2 cell line to examine the role of DUXAP8 in HCC cell proliferation and invasion. Results: DUXAP8 was significantly upregulated in various types of human cancers and could serve as a potential pan-cancer diagnostic and prognostic biomarker. Bioinformatics analysis suggested that DUXAP8 might be involved in the regulation of the biological processes of HCC cell cycle, cell division and cell proliferation. Additionally, downregulation of DUXAP8 inhibited HCC cell proliferation and invasion in vitro. Conclusion: This study revealed that DUXAP8 may serve as a potential pan-cancer prognostic and diagnostic marker in humans. In addition, DUXAP8 promoted HCC cell proliferation and invasion, suggesting that it may represent a novel therapeutic target for HCC.
基金:
First Hospital of Shanxi Medical University [YD1607]; Scientific Research Project Plan of Shanxi Provincial Health Planning Commission [2014029]; Fostering Team for Precision Medical Key Innovation in the First Hospital of Shanxi Medical University [YT1603]; Shanxi Medical University Doctor's Startup Fund Project [XD1802]
第一作者机构:[1]Capital Med Univ, Beijing Tongren Hosp, Dept Gen Surg, 1 Dongjiaominxiang, Beijing 100730, Peoples R China
共同第一作者:
通讯作者:
通讯机构:[1]Capital Med Univ, Beijing Tongren Hosp, Dept Gen Surg, 1 Dongjiaominxiang, Beijing 100730, Peoples R China[2]Shanxi Med Univ, Clin Med Coll 1, Dept Gen Surg, Hosp 1, 85 Jiefangnan Rd, Taiyuan 030001, Shanxi, Peoples R China[*1]Department of General Surgery, Beijing Tongren Hospital, Capital Medical University, No. 1 Dongjiaominxiang, Dongcheng District, Beijing 100730, People’s Republic of China[*2]Department of General Surgery, First Hospital/First Clinical Medical College of Shanxi Medical University, No. 85 Jiefangnan Road, Yingze District, Taiyuan, Shanxi 030001, People’s Republic of China
推荐引用方式(GB/T 7714):
Yue Chaosen,Liang Chaojie,Li Pengyang,et al.DUXAP8 a Pan-Cancer Prognostic Marker Involved in the Molecular Regulatory Mechanism in Hepatocellular Carcinoma: A Comprehensive Study Based on Data Mining, Bioinformatics, and in vitro Validation[J].ONCOTARGETS AND THERAPY.2019,12:11637-11650.doi:10.2147/OTT.S231750.
APA:
Yue, Chaosen,Liang, Chaojie,Li, Pengyang,Yan, Lijun,Zhang, Dongxin...&Wu, Jixiang.(2019).DUXAP8 a Pan-Cancer Prognostic Marker Involved in the Molecular Regulatory Mechanism in Hepatocellular Carcinoma: A Comprehensive Study Based on Data Mining, Bioinformatics, and in vitro Validation.ONCOTARGETS AND THERAPY,12,
MLA:
Yue, Chaosen,et al."DUXAP8 a Pan-Cancer Prognostic Marker Involved in the Molecular Regulatory Mechanism in Hepatocellular Carcinoma: A Comprehensive Study Based on Data Mining, Bioinformatics, and in vitro Validation".ONCOTARGETS AND THERAPY 12.(2019):11637-11650